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Abstract
Background: Adenotonsillectomy results in postoperative morbidity which otolaryngologists attempt to reduce by
use of antibiotics. The regimes used as quite varied with some opting for a full oral course postoperatively while
others prefer prophylactic doses. This randomised clinical trial done in Kenyatta National Hospital, Kenya had the
aim of comparing the efficacy of Co-Amoxiclav given as a single intravenous dose with a full oral course in the
prevention of post adenotonsillectomy morbidity.
Methods: 126 patients below 12 years scheduled to undergo adenotonsillectomy were randomised into two
groups. 63 were given a single intravenous dose of Enhancin [Co-Amoxiclav] at induction while the remaining half
received a five days oral course of the same postoperatively. All received oral Pacimol [Paracetamol] in the
postoperative period. Analysis was done and comparison made between the two groups with regards to pain,
fever and diet tolerated in the postoperative period with a follow up period of seven days.
Results: There was no statistical significant difference between the two groups with regards to postoperative pain,
fever and diet tolerated. All had a P-value > 0.2. Postoperative pain was highest in the first postoperative day and
reduced progressively to the lowest level on the 7
th postoperative day. As pain reduced, patients were able to
tolerate a more solid diet with all but 6 tolerating their usual diet. 4 patients developed fever in the 1
st
postoperative day which did not progress to the next day. One patient had fever on the 4
th and 7
th postoperative
day and was admitted in the paediatrics’ ward with a chest infection. All these patients with history of fever were
in the group that was on oral postoperative Co-Amoxiclav.
Conclusion: A single intraoperative dose of Co-Amoxiclav given intravenously at induction was found to be just as
effective as a full oral course of the same given postoperatively in the prevention of post adenotonsillectomy
morbidity. The prophylactic dose is favoured over the later as it is cheaper, ensures compliance and relieves off the
need for refrigeration of the oral suspension as not all have access to refrigeration in low economy countries as
ours.
Trial registration: ClinicalTrials.gov: NCT01267942
Background
Perioperative use of antibiotics has been shown to be
effective in reducing some of the morbidities of adeno-
tonsillectomy which include postoperative pain, fever
and haemorrhage among others [1]. The odynophagia
that results may limit food and fluid intake that could
result in dehydration. Infection of the operation site has
been thought to be a major contributor of the above for
which otolaryngologists attempt to prevent by use of
antibiotics.
Adenotonsillectomy is a clean contaminated operation
for which prophylaxis is indicated. This aims at reducing
microbial burden at the operation site as antibiotic is
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previously sterile tissues [2,3]. This relieves the need to
taking oral postoperative medication the compliance of
which may be suboptimal post adenotonsillectomy due
to odynophagia that results from traumatised pharyngeal
tissues with possibility of resistance development.
Widespread and often inappropriate use of broad-
spectrum antibiotics is responsible for development and
spread of bacterial resistance [4]. Rational use of antibio-
tic is required if development of virulent microorganism
is to be prevented. The current practice of antibiotic use
with regards to adenotonsillectomy is not standardised
as is evidenced by the varied regimes that have been
u s e dw o r l dw i d e[ 5 ] .S o m eo t o l a r y n g o l o g i s t sg i v ep o s t -
operative oral antibiotics, so m eg i v ef e wd o s e so fi n t r a -
venous antibiotics while others prefer no antibiotics.
Many studies have been done with regards to periopera-
tive antibiotic use with regards to adenotonsillectomy
none of which was found to focus on prophylactic single
preoperative intravenous antibiotic. This prompted us to
do this study which compares prophylactic doses of
Enhancin [Co-amoxiclav] with full postoperative oral
courses of the same.
Objective
To compare prophylactic doses of Co-Amoxiclav given
at induction with postoperative full oral course of the
same in their ability to reduce post adenotonsillectomy
mordity.
Methods
Study design
Randomised clinical trial.
Ethical approval
The protocol was reviewed and approved by Kenyatta
National Hospital; Ethics and Research Committee.
[P75/4/2008]
Setting
Kenyatta National Hospital [Kenya], ENT department.
Inclusion criteria
a. Patients below 12 years undergoing
adenotonsillectomy.
b. Consenting parents or guardians of patients under-
going surgery.
Exclusion criteria
a. Non-consenting parent or guardians of patients
undergoing surgery.
b. Antibiotic use in the preceding week prior to
admission.
c. Patients who develop complications that warranted
change of antibiotic or required hospitalisation eg. Poor
reversal from general anaesthesia.
d. Patients with co-morbid conditions like malnutri-
tion, anaemia etc.
e. Known allergies to Penicillin or Co-Amoxiclav.
Sample size determination
Sample size necessary to detect statistically significant
difference between test and control groups in reduction
of morbidity with Power of 80% and 5% significant level
was calculated using the formula below by Cyrus R.
Mehta [6].
2N =
4(Zα + Zβ)
2σ2
δ2
2N = Total number of patients in both arms of the
study.
Za = 1.96 for type 1 error of 5%.
Zb = 0.842 for type 2 error 20%.
s = Variance from other studies.
δ = Difference between test and control that is consid-
ered clinically significant.
From the calculations, a total number of 126 were
required for the study; 63 in each arm.
Trial design
The design was parallel with groups A and B. Group A
patients were to receive intravenous Enhancin [Co-
amoxiclav] while those in Group B were to receive post-
operative Enhancin [Co-amoxiclav].
The principle investigator used Permuted-block ran-
domisation with 2 blocks of equal size and an allocation
ratio of 1:1. Randomisation was done within each group
and allocation concealment achieved by sequentially-
numbered opaque and sealed envelops.
The patients were recruited by the principle investiga-
tor and allocated their respective groups as per the con-
tent of the sequentially-numbered opaque sealed
envelops.
Statististical analysis
Data was analysed using the SPSS computer pro-
gramme. The independent Student T test was used to
compare data from the two groups with calculation of
the t value for each of variables. This was subsequently
used to calculate the Probability value, which would
then determine significance of the observation made.
Procedure
Research numbers were given to the patients consecu-
tively from 1 to 126 once the study commenced. The
principle researcher didn’t participate in the surgeries.
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perform the operation reviewed the patients preopera-
tively. The surgeon performing the surgeries was blinded
but not the anaesthesiologist who gave the intravenous
dose of Enhancin to the patients in Group A. Overnight
admission was mandatory with starving of the patients
six hours prior to surgery.
The patients were taken to the operating room the
following day and Atropine was given half an hour
before surgery to dry bronchial and oral secretions at a
dose of 20 micrograms per kilogram [7].
Patients in group A received intravenous Enhancin
[Co-Amoxiclav] at induction at a dose of 25 mg/kg and
Pacimol [Paracetamol] suppositories 125 mg for patients
under 5 years and 250 mg for those above 5 years [8].
Oral Pacimol [Paracetamol] was given to them in the
postoperative period at a dose of 10 mg/kg [9].
Those in group B received Atropine and Pacimol
[Paracetamol] at a similar timing and dose as those in
group A. They however receive oral Enhancin [Co-
Amoxiclav] for 5 days in the postoperative period at a
dose of 25 mg/kg expressed as Amoxycillin [8]. No
intraoperative Enhancin [Co-Amoxiclav] was given to
patients in this group.
Tonsillectomy was done by blunt dissection while ade-
noidectomy by curettage. Diathermy or pressure packing
achieved haemostasis. Documentation was done appro-
priately in forms that were made available in theatre.
The patients were discharged the day following sur-
gery. Any complication in the general condition that
arose was investigated and appropriate management
given.
Patients, guardians or parents were advised to look
out for haemorrhage, postoperative fever, severe odyno-
phagia and vomiting in the postoperative period. They
were advised to present themselves to hospital immedi-
ately for review in case there were changes in their gen-
eral condition that gave concern. The principal
researcher gave his mobile phone number to all those in
the study and flash back services was used in case any
information requirement arose.
Outcomes
A blinded reviewer collected data for the outcomes
listed below on the 1
st,4
th and 7
th postoperative days.
He didn’tk n o wt h a tt h ep a t i e n t sw e r es p l i ti nt w o
groups or the different medication given to either.
Comparison between the two groups was done with
special emphasis on the outcomes below.
1. Postoperative pain was assessed using a visual ana-
logue scale. The parents or guardians would be shown
the scale and explained to on how it was used. They
would then be asked to estimate the amount of pain
they thought their patients were experiencing and
indicate the same on a scale of 0 to 10 with 0 being ‘no
pain’ and 10 being ‘the worst imaginable pain’. This was
assessed once on the 1
st,4
th and 7
th postoperative days.
2. Fever was defined by a temperature reading that
was more than 37.2 degree on Celsius scale taken by
thermometer in the axilla. A thermometer was placed in
the axilla of the patient till it made an alert sound indi-
cating that the maximum temperature had been
attained.
Temperature was taken 4 hourly in the postoperative
period till the patients were discharged and on presenta-
tion during the follow up period.
3. Return to normal diet was assessed by the duration
of time taken for the patient to start taking his usual
diet after surgery. A progressive assessment was done
with regards on the diet consistency the patients were
tolerating with the options of ‘nil’, ‘liquid’, ‘semisolid’
and ‘usual’.
This was documented once on the days of review.
Results
Drop Out
There was a drop out of 10.6% as total of 141 patients
were recruited into the study with 15 being excluded
due to various reasons. The remaining 126 patients, 63
in each group were analysed.
The excluded had 5 patients in Group B who were
given postoperative Amoxycillin instead of Enhancin
[Co-Amoxiclav]. 2 patients in Group A were erro-
neously prescribed for postoperative oral Enhancin [Co-
Amoxiclav] after they had already received the single
intraoperative intravenousd o s eo ft h ea n t i b i o t i c .8
patients failed to turn up for review, 4 in either group.
Age
All the patients recruited into the study were below the
age of twelve years with a mean of 4 years for both
groups. The maximum age recruited for Group A was 7
years and 9 years for Group B. The minimum age was
1.5 years for either groups.
Sex
More males were recruited into the study than females
in both groups. 36 of the 63 in Group A were male
forming 57% while they were 74% in Group B as 47 of
the 63 were of the said gender.
Indication For Surgery
In order to standardise the study, only patients under-
going both adenoid and tonsillar surgery were recruited.
Thus the indications for surgery fell in two groups. One
group had obstructive symptoms due to adenoid and
tonsillar hypertrophy while the other group had chronic
recurrent tonsillitis and adenoid hypertrophy. Group A
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Group B had 53 of the 63 with this indication. This
translates to 79% and 84% in Group A and Group B
respectively.
Analysis of pain
The visual analogue scale was used to evaluate pain the
patients were experiencing postoperatively at day 1, 4
and 7.
Patients in both groups reported a high score in the
first postoperative day with reduction of the same with
all reporting lowest levels at day 7.
Comparison between the two groups was made using
the Students T test [independent sample test] at day 1,
4 and 7.
In all the days analysed, thresholds required to reject the
null hypothesis were not reached. Thus, with regards to
pain, there was no demonstrable difference between a sin-
gle dose of intravenous Enhancin [Co-Amoxiclav] given at
induction and a full oral postoperative course of the same.
Diet
The diet that the patients could take was assessed at day
1, 4 and 7. Generally it was noted that as the days
passed after the surgery, the patients could tolerate
more solid feeds as is expected.
There were no statistical significant differences
between the two groups.
The Students T test [independent sample test] was
used to compare the groups with regards to feeds on
subsequent days. The two groups were not found to
have any statistical difference with regard to feeds on all
the days that were analysed. Thus there was no demon-
s t r a b l ed i f f e r e n c eb e t w e e nas i n g l ei n t r a v e n o u sd o s eo f
Co-Amoxiclav given at induction and a full oral post-
operative course of the same with regards to resumption
to usual diet after operation.
Temperature
No patient had fever on the day of the operation in both
groups. On the first postoperative day 4 patients all in
group B had fever. None in group A had fever.
On the 4
th postoperative day, only 1 patient in group
B had fever. This patient was not among those who had
fever on the 1
st postoperative day. No patient in group
A had fever.
On the 7
th postoperative day, the same patient who
had presented with fever on the 4
th postoperative day
had fever. This patient was admitted in the paediatric
ward the following day with a chest infection. He had
taken Enhancin [Co-Amoxiclav] and Pacimol [Paraceta-
mol] for five days as had been instructed.
Analysis of the two groups with regards to tempera-
ture was made with the Students T test [independent
sample test]. There was no statistical significant differ-
ence between the two groups. It can thus be deduced
that there is no difference between a single intravenous
dose of Enhancin [Co-Amoxiclav] given at induction
and a full oral postoperative course of the same in pre-
vention of postoperative infection.
For all of the outcomes analysed, none was found to
have statistically significant difference (Table 1).
Discussion
Fever in the postoperative period could be due to infec-
tion or as a response to tissue injury. Both conditions
give rise to pyrogenic cytokines that cause production of
Prostaglandin E 2 with resetting of the hypothalamic
thermal setpoint. Interleukin 2 has been identified as an
important intracellular messenger in the development of
fever whether due to trauma or infection [10].
Fever that develops during the first two days post-
operatively is usually regarded to be due to the body’s
response to trauma while that which develops later is
likely to have an infective pathophysiology. 4 patients
developed fever in the first postoperative day, which by
the second day had resolved. All belonged to group B
and were on oral Enhancin [Co-Amoxiclav] and Pacimol
[Paracetamol]. All had low-grade fever as none had tem-
perature more than 38 degrees Celsius. They formed
3.1% of all the patients in the study compared to 54% in
V.T Anand’s study of postoperative fever in paediatrics
after tonsillectomy [11]. In the later study, temperature
was monitored 2 hourly after surgery in the first 24
hours while it was monitored 4 hourly in this current
study with documentation starting the day after surgery.
This could mean that some patients might have had
developed fever but not captured as monitoring in the
first 24 hours was not done comprehensively. It was
also not considered whether Dexamethasone was or not
given during the surgery asi st h ep r a c t i c eo fs o m e
anesthesiologists. This could suppress the inflammatory
response in the first 24 hours therefore reducing those
with fever in the immediate postoperative period.
The effect of Pacimol [Paracetamol] should also be
taken into account due to its antipyretic activity. It was
not considered whether the antipyretic was given before
or after the temperatures were taken.
Table 1 Table representing outcome
Outcome Pain Diet Temperature
D a y 147147147
Tvalue -0.09 1.489 -0.60 -1.08 0.779 0.832 -2.05 -1.00 -1.00
Df 124 124 124 124 124 124 124 124 124
Pvalue >0.2 >0.2 >0.2 >0.2 >0.2 >0.2 >0.2 >0.2 >0.2
Significance Nil Nil Ni Nil Nil Nil Nil Nil Nil
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to group B and was on oral Enhancin [Co-Amoxiclav]
and Pacimol [Paracetamol] and didn’t have fever at day
1. He was admitted in the paediatric ward and treated
for pneumonia with intravenous drugs and discharged 5
days later.
Analysis of Enhancin [Co-Amoxiclav] given as a single
dose at induction and the same given orally postopera-
tively show no difference in their ability to prevent post-
operative infection, which presents clinically as fever.
Pain in the postoperative period result from trauma to
the surrounding tissues during surgery, diathermy or
ligation especially if the constrictors are involved. Infec-
tion gives rise to inflammation, which causes increase in
pain being experienced by a patient. Pain in the first
two postoperative days is due to trauma to the sur-
rounding tissues while an increase in pain at a later day
may be a pointer to infection. Pain may restrict feeds
and fluids intake that may result in dehydration. Com-
pliance to oral medication in the postoperative period
could be suboptimal due to odynophagia with selection
of resistant microorganisms. In the study, pain was
noted to be highest in the first postoperative day and
least on the 7
th. It is expected that in the absence of
infection, pain should decrease with progressive healing
of the tissues which allows the patients to tolerate more
solid feeds as the discomfort in the oropharynx reduces.
The patient who developed a chest infection on the
4
th postoperative day was on soft feeds on the said and
7
th day. He was not able to take his usual diet on the
7
th day. He didn’t have infection in the tonsillar region
and the inability to take his usual diet could have been a
misinterpretation of anorexia, which is an attendant of
respiratory tract infection.
Analysis of the two groups with regards to postopera-
tive pain and diet showed no statistical significance.
This means that a single dose of Enhancin [Co-Amoxi-
cav] given at induction is just as effective as a full oral
course of the same given postoperative period with
regards to pain and diet, which in effect reflects on
healing.
Colveary M.P et al. did a study on the postoperative
effect of Amoxycillin/Clavulinic acid in post tonsillect-
omy patients with regards to postoperative pain and diet
tolerated. They compared a group of patient given the
antibiotic orally postoperatively with patient not given.
Antibiotic use was found to be useful in reducing mor-
bidity postoperatively as judged by the amount of
analgesics used (P = 0.379), time to resume normal diet
(P = 0.0072) and visual analogue scale (P = 0.0006) [1].
They didn’t consider postoperative fever in their study.
Fennesby B.G et al found level 1 evidence that antibio-
tics reduce the incidence of postoperative fever, oro-
pharyngeal pain and return to normal activity post
tonsillectomy [12]. The authors had done literature
review through Pubmed in an attempt to identify the
level of evidence for or against the use of prophylaxis
for various ear, nose and throat surgeries. These, in
addition to other studies confirms that antibiotics
reduce morbidity post tonsillectomy. Thus adenotonsil-
lectomy patients not given antibiotics are expected to
present with a higher incidence of postoperative fever,
pain and take longer to tolerate their normal diet. Our
study has shown that both a prophylactic dose and full
postoperative dose of antibiotic have equal efficacy in
the prevention of postadenotonsillectomy morbidity.
H a dat h i r da r mb e e na d d e dt ot h es t u d yi nw h i c h
patients were not given antibiotics, more pain, higher
incidence of fever and delayed return to normal diet is
to be expected. These studies differ with ours as we
focus on prophylaxis with regards to adenotonsillect-
omy. Colveary’study though titled: ‘Antibiotic prophy-
laxis post-tonsillectomy is it of benefit’ doesn’tp a s sa s
prophylaxis as the antibiotic was given orally postopera-
tively. The principles of prophylaxis require the antibio-
tic to be given intravenously at induction as a stat dose
so as to have adequate concentrations in the tissues
before incision [13]. Studies that were found to use sin-
gle doses of antibiotic didn’t pass as prophylactic either
as the antibiotic was either given orally preoperatively or
postoperatively. No study was found that focused on
single intravenous preoperative antibiotic in the reduc-
tion of postoperative morbidity as this is the require-
ment for qualification as prophylaxis.
It is due to this that we think that our study sheds
more light with regards to prophylaxis which the study
h a sp r o v e nt ob ej u s ta se f f e c t i v ea sp o s t o p e r a t i v ef u l l
oral course.
Shortcomings of the Study
Blinding of the parents/patients was not done. This
could have had an effect on the subjective outcomes like
pain and diet tolerated. The objective outcome of tem-
perature was not affected by the lack of blinded stated
above.
Conclusions
From the study’s results and their analysis, a single
intraoperative dose of Enhancin [Co-Amoxiclav] given
at induction is just as effective as full oral postoperative
course of the same in prevention of post adenotonsil-
lectomy morbidity.
The fore mentioned medication is cheaper as it is
given once and compliance is assured. Emergence of
resistant and virulent microorganisms is prevented by
this prophylactic medication, as compliance to oral
medication in patients post adenotonsillectomy is not
assured due to odynophagia.
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once reconstituted so as to ensure potency. As refrigera-
tion might not be available in some of the homes of the
patients, a single dose at induction circumvents the
predicament.
Ap r o p h y l a c t i cs i n g l ed o s eo fE n h a n c i n[ C o - A m o x i -
clav] given at induction is thus recommended.
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